Actively Recruiting
Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death
Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2026-04-08
300
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute coronary syndrome (ACS) is a leading cause of death worldwide, involving conditions like acute myocardial infarction and unstable angina that can trigger sudden cardiac death (SCD). This research focuses on understanding the early clinical signs and prognosis of patients who experience sudden death linked to ACS. The study aims to evaluate exosome multiomics, including metabolites, microRNAs, and proteins, to better predict and manage SCD risk in ACS patients. Participants will receive standardized medical care for cardiac arrest, which includes early cardiopulmonary resuscitation (CPR), defibrillation, advanced cardiac life support (ACLS), and post-resuscitation care with continuous monitoring. The study is observational and monitors patients over a period of two years to assess the presence of exosome-associated biomarkers. No experimental drugs are administered; instead, patient outcomes following standard emergency care are observed. Participants will be monitored through clinical evaluations and laboratory tests assessing exosome-related molecules over two years. Researchers will examine these biomarkers to understand their connection with sudden death outcomes. The study also tracks vital signs and clinical symptoms before and after treatment, aiming to improve early prediction of SCD in ACS patients. The total duration of participation spans up to two years with regular follow-ups to assess prognosis and biomarker changes.
CONDITIONS
Brief Title
Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The death event happens suddenly.
- Age 65 18 years
- The patient had obvious clinical symptoms 24 hours before treatment
- Life expectancy exceeds 3 days
- Proxy of patients signs the informed consent form
- Comply with ACS diagnostic indicators recommended by ACC / AHA guidelines in 2016
You will not qualify if you...
- Death caused by accident, such as trauma, poisoning, etc.
- Death from accidental or intentional overdose
- Death from asphyxia
- Death is caused by chronic disease or terminal illness
- The patient died naturally
- Has participated in other clinical studies
- Immediate family members give up continuing treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants who undergo standardized medical care of cardiac arrest are observed for the presence of exosome-associated metabolites, microRNAs, and proteins.
Follow-up visits as scheduled over 2 years
Trial Site Locations
Total: 1 location
1
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China, 210008
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here